Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

181. Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life

Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life Nikander R, Sievanen H, Heinonen A, Daly RM, Uusi-Rasi K, Kannus P CRD summary The review concluded that there was a small (...) School of Musculoskeletal Disorders and Biomaterials and the Paivikki and Sakari Sohlberg Foundation. Bibliographic details Nikander R, Sievanen H, Heinonen A, Daly RM, Uusi-Rasi K, Kannus P. Targeted exercise against osteoporosis: a systematic review and meta-analysis for optimising bone strength throughout life. BMC Medicine 2010; 8:47 PubMedID DOI Original Paper URL Other URL Indexing Status Subject indexing assigned by NLM MeSH Bone and Bones /physiology; Exercise Therapy /methods; Female; Humans

DARE.2010

182. Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment

Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment. Lansdale: HAYES, Inc.. 2010 Authors' conclusions Urinary cross-linked N-telopeptide of type collagen (NTx) is a biochemical marker of bone resorption. Urinary NTx can be measured noninvasively in the urine, and serum NTx can be quantified from blood. Urinary NTx has been recently proposed as an independent or complementary tool to bone mineral density (BMD) measures to identify bone loss, assess

Health Technology Assessment (HTA) Database.2010

183. Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment

Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment. Lansdale: HAYES, Inc.. 2010 Authors' conclusions Urinary cross-linked N-telopeptide of type I collagen (NTx) is a biochemical marker of bone resorption. Urinary NTx can be measured noninvasively in the urine, and serum NTx can be quantified from blood. Urinary NTx has been recently proposed as an independent or complementary

Health Technology Assessment (HTA) Database.2010

184. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review

Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review Mamtani M, Kulkarni H CRD summary The authors concluded that zoledronate was a promising bisphosphonate that improved bone mineral density in thalassaemia (...) -induced osteoporosis, but that more research is required to understand its potential adverse effects. The review suffered from poor reporting and had potential methodological weaknesses, including the uncertain quality of included trials, which limits the reliability of the authors’ conclusion. Authors' objectives To evaluate the effectiveness of zoledronate for the treatment of thalassaemia-induced osteoporosis. Searching MEDLINE, EMBASE, and CINAHL were searched for published studies. Search terms

DARE.2010

186. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of risedronate, compared with no intervention, for the prevention and treatment of osteoporosis in post-menopausal women, aged 50 years or older, who had various absolute risks of fracture, assessed using the World Health Organization's FRAX tool. From the perspective

NHS Economic Evaluation Database.2010

187. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of strontium ranelate for osteoporosis treatment in post-menopausal women, with clinical risk factors, identified by the World Health Organization's fracture risk assessment tool; FRAX. Strontium ranelate was cost-effective for the treatment of established osteoporosis in women over the age of 65

NHS Economic Evaluation Database.2010

188. Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis

Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis Fardellone P, Cortet B, Legrand E, Bresse X, Bisot-Locard S, Vigneron AM, Beresniak A Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of a single infusion of zoledronic acid against current treatment strategies for postmenopausal osteoporosis in France. The authors concluded that zoledronic acid

NHS Economic Evaluation Database.2010

190. Osteodensitometry in primary and secondary osteoporosis

Osteodensitometry in primary and secondary osteoporosis Osteodensitometrie bei primärer und sekundärer osteoporose [Osteodensitometry in primary and secondary osteoporosis] Osteodensitometrie bei primärer und sekundärer osteoporose [Osteodensitometry in primary and secondary osteoporosis] IQWiG Citation IQWiG. Osteodensitometrie bei primärer und sekundärer osteoporose. [Osteodensitometry in primary and secondary osteoporosis] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im (...) Gesundheitswesen (IQWiG). IQWiG-Berichte 73. 2010 Authors' conclusions The key question of the present report was whether women or men with primary or secondary osteoporosis (but without pre-existing osteoporotic fractures) benefit from a health care strategy containing a diagnostic procedure (osteodensitometry) for determining low BMD and an increased fracture risk, as well as containing subsequent treatment, compared to a strategy without such an intervention. Due to the lack of studies with certainty

Health Technology Assessment (HTA) Database.2010

191. Effect of osteoporosis treatment on mortality: a meta-analysis

Effect of osteoporosis treatment on mortality: a meta-analysis Effect of osteoporosis treatment on mortality: a meta-analysis Effect of osteoporosis treatment on mortality: a meta-analysis Bolland MJ, Grey AB, Gamble GD, Reid IR CRD summary This review concluded that effective treatments for fracture prevention in osteoporosis reduced mortality in older, frailer individuals with osteoporosis who were at high risk of fracture. Weaknesses in the review methods and reporting and interpretation (...) of results mean that these conclusions should be viewed cautiously. Authors' objectives To determine whether effective osteoporosis treatment reduced mortality. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to September 2008. Search terms were reported. Bibliographies of recent meta-analyses of treatment for osteoporosis and retrieved articles were screened for additional studies. Conference abstracts of American Society for Bone and Mineral Research annual

DARE.2010

192. Fracture prediction and the definition of osteoporosis in children and adolescents: the 2007 ISCD pediatric official positions.

Fracture prediction and the definition of osteoporosis in children and adolescents: the 2007 ISCD pediatric official positions. Fracture prediction and the definition of osteoporosis in children and adolescents: the 2007 ISCD pediatric official positions. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006920 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all

International Society for Clinical Densitometry2010

193. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD official positions.

Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD official positions. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD official positions. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006917 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines

International Society for Clinical Densitometry2010

194. Peripheral dual-energy x-ray absorptiometry in the management of osteoporosis: the 2007 ISCD official positions.

Peripheral dual-energy x-ray absorptiometry in the management of osteoporosis: the 2007 ISCD official positions. Peripheral dual-energy x-ray absorptiometry in the management of osteoporosis: the 2007 ISCD official positions. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006916 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About

International Society for Clinical Densitometry2010

195. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD official positions.

Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD official positions. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD official positions. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006915

International Society for Clinical Densitometry2010

196. Osteoporosis disease management - what every orthopaedic surgeon should know

Osteoporosis disease management - what every orthopaedic surgeon should know British Orthopaedic Association : Publications to Download BOA Member Login BOA Number Password Search remember me > Publications > Publications to Download Publications to Download Please note that additional publications are referenced from the side navigation menu item "Publications". If you are a current BOA Member who is not logged in, then you will only see "public" documents. To log in, go to the login boxes

Publication 10832010

197. Lasofoxifene in postmenopausal women with osteoporosis.

Lasofoxifene in postmenopausal women with osteoporosis. 20181970 2010 02 25 2010 03 09 2014 11 20 1533-4406 362 8 2010 Feb 25 The New England journal of medicine N. Engl. J. Med. Lasofoxifene in postmenopausal women with osteoporosis. 686-96 10.1056/NEJMoa0808692 The effects of lasofoxifene on the risk of fractures, breast cancer, and cardiovascular disease are uncertain. In this randomized trial, we assigned 8556 women who were between the ages of 59 and 80 years and had a bone mineral density (...) ; hazard ratios, 2.67 [95% CI, 1.55 to 4.58] and 2.06 [95% CI, 1.17 to 3.60], respectively). Endometrial cancer occurred in three women in the placebo group, two women in the lower-dose lasofoxifene group, and two women in the higher-dose lasofoxifene group. Rates of death per 1000 person-years were 5.1 in the placebo group, 7.0 in the lower-dose lasofoxifene group, and 5.7 in the higher-dose lasofoxifene group. In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day

NEJM2010

198. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society

Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society

The North American Menopause Society2010

200. Q&A Potpourri ? Osteoporosis, Vit D, Self-Monitoring of Blood Glucose, and Anti-Infectives

Q&A Potpourri ? Osteoporosis, Vit D, Self-Monitoring of Blood Glucose, and Anti-Infectives

RxFiles2010